Advertisement
Mergers and Acquisitions
Subscribe to Mergers and Acquisitions

The Lead

Cocrystal Pharma and RFS Pharma Merge to Create Antiviral Development Organization

November 25, 2014 11:10 am | News | Comments

Cocrystal Pharma, a biotechnology company developing novel antiviral therapeutics for human diseases, today announced the closing of its merger with RFS Pharma, a privately owned biotech company founded by renowned drug developer, Dr. Raymond Schinazi.

Health Care M&A Leads Global Deal Surge

November 24, 2014 8:35 am | by LINDA A. JOHNSON, AP Business Writer; STEVE ROTHWELL, AP Business Writer | News | Comments

In a big year for deal making, the health care industry is a standout. Large drugmakers are...

BioMarin Pharma Offers $680M for Prosensa

November 24, 2014 8:10 am | News | Comments

BioMarin Pharmaceutical will pay $680 million in cash for the Dutch biotech company Prosensa in...

Apellis Pharmaceuticals to Acquire Potentia Pharmaceuticals

November 20, 2014 8:00 am | News | Comments

Apellis Pharmaceuticals has entered into an agreement to acquire Potentia Pharmaceuticals. As...

View Sample

FREE Email Newsletter

GlobalData Director: Actavis Continues Consolidation March with Highly Priced Allergan Deal

November 18, 2014 8:21 am | News | Comments

According to Joshua Owide, GlobalData’s Director of Healthcare Industry Dynamics, "The integration of Allergan and Forest will help grow Actavis to a $22 billion healthcare company in 2015. This is a dramatic elevation from its $8.7 billion revenues recorded in 2013, the year in which Actavis completed the $5 billion acquisition of Warner Chilcott."

Actavis to Spend $66B on Allergan

November 17, 2014 10:24 am | by TOM MURPHY, AP Business Writer | News | Comments

Actavis will pay $66 billion to buy fellow drugmaker Allergan in a deal that could finally stop a months-long takeover push from Valeant Pharmaceuticals for the Botox maker.             

Allergan Soars on Deal Reports

November 17, 2014 8:11 am | by The Associated Press | News | Comments

Shares of Allergan jumped in premarket trading Monday after several reports surfaced over the weekend that specialty drugmaker Actavis was preparing to buy the maker of Botox, which is embroiled in a takeover battle with Valeant Pharmaceuticals.

Advertisement

Zoetis Adopts Shareholder Rights Plan

November 14, 2014 6:11 pm | by The Associated Press | News | Comments

Zoetis Inc. said Friday that it has adopted a one-year shareholder rights plan. These plans, often known as "poison pills", are intended to fight off hostile takeovers. Zoetis said the plan would enable existing shareholders a right to buy preferred stock if a person or group acquires at least 15 percent of the company's stock and tries to buy more.

Ackman Takes Stake in Animal-Health Company Zoetis

November 13, 2014 12:09 pm | Videos | Comments

Activist investor William Ackman has taken a roughly $2 billion stake in Zoetis and could push the animal-health company to sell itself to a larger drug maker.               

Golden Gate Capital Acquires ANGUS Chemical Company

November 12, 2014 3:12 pm | News | Comments

Golden Gate Capital today announced that it has entered into a definitive agreement to acquire ANGUS Chemical Company from The Dow Chemical Company for $1.215 billion.              

Allergan Amends Company’s Bylaws Prior to Stockholder's Meeting

November 12, 2014 8:12 am | News | Comments

Allergan today announced that its Board of Directors has approved amendments to the company’s bylaws that streamline the process associated with calling a special meeting of stockholders. The Board determined to amend the bylaws after meetings with many of the Company’s major stockholders and other governance organizations to solicit their input and perspectives.

Eurofins Acquires SF Analytical Labs

November 6, 2014 2:17 pm | News | Comments

Eurofins Scientific has announced the pending acquisition of SF Analytical (SFA) Laboratories. The transaction will close at the end of November. The acquisition strengthens Eurofins' growing presence in the US, as well as expands the current base of operations in the Midwestern United States.

Advertisement

Perrigo to Acquire Omega Pharma

November 6, 2014 8:26 am | News | Comments

Perrigo Company and Omega have entered into a definitive agreement in which Perrigo has agreed to acquire Omega for EUR3.6 billion, or $4.5 billion, comprised of the purchase of Omega's equity for EUR2.48 billion and the assumption of EUR1.1 billion in debt.

GVK BIO to Acquire Vanta Bioscience

November 6, 2014 8:16 am | News | Comments

GVK BIO has announced the signing of a definitive agreement to acquire Vanta Bioscience, a full service preclinical GLP toxicology and safety assessment contract research organization operating out of Chennai, India.      

Allergan Deal Inches Forward with Court's Decision

November 4, 2014 6:01 pm | by The Associated Press | News | Comments

In a win for Valeant and Pershing Square, a federal judge has decided that they can vote in takeover target Allergan's upcoming shareholder meeting.  Allergan said in a statement Tuesday that it will file an emergency appeal.    

LabCorp to Spend $6.1B on Covance

November 3, 2014 7:35 pm | by The Associated Press | News | Comments

LabCorp will pay about $6.1 billion in cash and stock to buy Covance in a tie-up that aims to improve clinical trial research for pharmaceuticals.                  

Bristol-Myers Squibb to Acquire Galecto Biotech AB and Its Novel Galectin-3 Inhibitor

November 3, 2014 7:31 pm | News | Comments

Bristol-Myers Squibb and Galecto Biotech AB have entered into an agreement that provides Bristol-Myers Squibb the exclusive option to acquire Galecto Biotech AB and gain worldwide rights to its lead asset TD139, a novel inhaled inhibitor of galectin-3 in Phase 1 development for the treatment of idiopathic pulmonary fibrosis and other pulmonary fibrotic conditions.

Advertisement

Actavis and Durata Therapeutics FTC Clearance for Actavis' Proposed Acquisition of Durata

November 2, 2014 5:34 pm | News | Comments

Actavis and Durata Therapeutics have  announced that the FTC has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to Actavis' pending acquisition of Durata.

Lubrizol Forms Alliance with Particle Sciences after Vesta Acquisition

October 31, 2014 8:58 am | News | Comments

The Lubrizol Corporation has announced an alliance between Lubrizol LifeSciences, a supplier of advanced materials for the healthcare industry, and Particle Sciences, an integrated provider of drug development services.     

Chinese Pharma Firm to Establish Operations in Virginia

October 30, 2014 12:56 pm | News | Comments

Virginia's Gov. Terry McAuliffe said Thursday that UniTao Pharmaceuticals LLC has purchased the Boehringer Ingelheim plant that's slated to close by the end of the year.              

Fujifilm to Buy U.S. Vaccine Maker to Expand Biopharma Business

October 27, 2014 8:56 am | News | Comments

Fujifilm will acquire U.S. vaccine maker Kalon Biotherapeutics to expand its biopharmaceutical business, with the Japanese firm having gained prominence for offering a possible treatment for Ebola patients.        

CSL to Acquire Novartis' Influenza Vaccine Business

October 27, 2014 8:43 am | News | Comments

CSL Limited today announced that it has agreed to acquire Novartis' global influenza vaccine business for US$275 million. The business will be combined with CSL's subsidiary, bioCSL.            

Zogenix Acquires U.K.-Based Brabant Pharma

October 27, 2014 8:24 am | News | Comments

Zogenix, Inc. today announced that it acquired Brabant Pharma, a privately-held U.K.-based pharmaceutical company for $20 million in cash and $15 million in stock plus potential future milestone and royalty payments.      

Valeant: We'll Bump Allergan Offer to $200 a Share

October 27, 2014 7:33 am | by The Associated Press | News | Comments

Valeant Pharmaceuticals International says it will raise its offer for Botox maker Allergan to $200 or more per share. Valeant made the statement in a letter to Allergan's board released publicly seeking to urge Allergan to talk about an acquisition.

Sutro Biopharma and Celgene Corporation Enter Multi-Year Strategic Collaboration and Option to Acquire Agreement

October 23, 2014 10:31 am | News | Comments

The scope of the collaboration allows the parties to systematically interrogate the immuno-oncology space, including established targets, using Sutro’s cell-free biologics development platforms. During the collaboration, after an initial period, Celgene will have the exclusive option to acquire Sutro, including rights to all Sutro-owned programs at that time, on pre-specified terms.

GlobalData Analyst: Pharmaceutical Industry Feeling Force of Tax Inversion Legislation

October 23, 2014 9:30 am | News | Comments

The recent termination of AbbVie’s deal to acquire Shire makes this pharmaceuticals’ first major casualty of new US tax inversion legislation, and has jolted the industry out of its reverie, according to an analyst with research and consulting firm GlobalData.

Hedge Fund Third Point Urges Amgen to Consider Breakup

October 22, 2014 8:24 am | by The Associated Press | News | Comments

A hedge fund run by a famed investor has taken a large stake in Amgen and now wants the biotech drugmaker to consider splitting up into two. In a letter to investors, Third Point, a hedge fund run by Daniel Loeb, said it has recently increased its stake by an unspecified amount, making it one of the drugmaker's top shareholders.

AbbVie to Pay Shire $1.64B Fee Over Canceled Merger

October 21, 2014 8:13 am | News | Comments

AbbVie is walking away from its proposed $55 billion takeover bid of Shire and has agreed to pay the rival drugmaker a $1.64 billion breakup fee. The two companies said the deal was off following the decision last week by AbbVie's board to withdraw support from the proposed acquisition.

Valeant Considering Higher Bid for Allergan after Reporting Strong Q3 Results

October 20, 2014 1:26 pm | by Ross Marowits, The Canadian Press | News | Comments

Valeant Pharmaceuticals said that its strong third-quarter results and a higher growth forecast give it ammunition to win over reluctant takeover target Botox maker Allergan with an increased bid at the appropriate time.     

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading